Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1522-1526

  Belur, Lalitha R ^a   Boelk Galvan, Debra ^a   Diers, Miechaleen D ^a   Scott McIvor, R ^a   Zimmerman, Cheryl L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW; BONE MARROW TRANSPLANTATION; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; INTESTINES; METHOTREXATE; MICE; MICE, TRANSGENIC; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0035866386     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. The clinical pharmacology of methotrexate
2. The pharmacology and clinical use of methotrexate
3. The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic acid reductase and of DNA synthesis
4. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse
5. Drug-resistant dihydrofolate reductases: Generation, expression and therapeutic application
6. Isolation and expression of an altered mouse dihydrofolate reductase cDNA
7. Site-directed mutagenesis of mouse dihydrofolate reductase. Mutants with increased resistance to methotrexate and trimethoprim
8. 31 substitutions
9. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31: A variety of amino acid substitutions conferring methotrexate resistance
10. Comparative methotrexate resistance of transgenic mice expressing two distinct dihydrofolate reductase variants
11. 22 variant of murine DHFR: Protection of transgenic marrow transplant recipients from lethal doses of methotrexate
12. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity
13. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow
14. Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells
15. Long term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase
16. A gene transfer strategy for making bone marrow cells resistant to trimetrexate
17. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: Association with significant decreases in creatinine clearance and renal clearances of the drug after 6 months of therapy
18. Analogs of Pteroylglutamic acid. III. 4-Amino derivatives
19. Assay for 4-amino folic acid analogues by inhibition of folic acid reductase
20. Techniques for study of resistance to folic acid antagonists
21. Enzymatic assay for methotrexate in serum and cerebrospinal fluid
22. Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader
23. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high dose methotrexate in murine tumor models
24. Tissue distribution of folate antagonists
25. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man
26. Uptake of methotrexate, aminopterin, and melhasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine
27. Threshold methotrexate concentrations for in vivo inhibition of DNA synthesis in normal and tumorous tissues
28. A study of the distribution of methotrexate in human tissues and tmnors
29. Pharmacokinetics of high dose methotrexate (NSC-740)
30. Intrinsic and acquired resistance to methotrexate in acute leukemia
31. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia
32. Selective treatment of SCID mice bearing methotrexate transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection
33. Retrovirus-mediated transfer and expression of drug resistance genes in human hematopoietic progenitor cells
34. Transfer and expression of the human multiple drug resistance gene into live mice
35. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
36. Resistance to Taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit
37. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea
38. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent
39. 34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance
40. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction
41. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene
42. Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance
43. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts
44. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22
45. Variants of human dihydrofolate reductase with substitutions at leucine 22: Effect on catalytic and inhibitor binding properties
46. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy